Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. reports developments in molecular diagnostics, including its patented platform for designing molecular diagnostic tests and its Co-Dx PCR platform. Company news commonly covers clinical and regulatory disclosures, commercialization activity through CoSara and CoMira joint ventures, intellectual property and technology updates, and operating and financial results.
Recurring updates also include material agreements, governance matters, capital-structure actions, and securities-listing developments. The company’s public disclosures connect its diagnostic-test pipeline, platform development, and commercialization strategy with financing, shareholder approvals, and other corporate actions.
Co-Diagnostics (Nasdaq: CODX) announced that its Logix Smart™ COVID-19 Test Kit was utilized by Italian researchers to detect SARS-CoV-2, including mutated strains, through community surveillance testing of discarded saliva samples. The peer-reviewed results were published in Science of the Total Environment. The study involved testing items like plastic cups and bottles across 20 sites in Northern Italy during the COVID-19 peak in early 2021. CEO Dwight Egan emphasized the importance of this study, highlighting the test's effectiveness in identifying viral presence in environmental samples.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) will showcase its innovations at the 13th Annual Next Generation Dx Summit from August 24-26, 2021, in Washington, D.C. The summit focuses on critical issues in diagnostics, featuring streams on Point-of-Care Testing (POCT) and Liquid Biopsy. CEO Dwight Egan is scheduled to present on August 25 at 10:30 am ET, discussing a rapid PCR diagnostics platform designed for POCT applications that aim to streamline testing protocols across various environments. More information on the summit can be found at Next Generation Dx.
Co-Diagnostics, Inc. (NASDAQ: CODX) reported second-quarter financial results with revenue of $27.4 million, a 13.8% increase year-over-year, driven by the Logix Smart™ COVID-19 Test. Gross profit rose 37.6% to $24.9 million, due to improved production costs. However, operating income fell 19.8% to $11.8 million due to rising sales and marketing expenses. Net income was $9.8 million ($0.33 per share), down from $15.0 million ($0.51 per share) a year earlier. Cash reserves increased to $72.4 million. The company expects Q3 revenue between $23.0 million and $25.0 million.
Co-Diagnostics, Inc. (Nasdaq: CODX) will release its second quarter 2021 financial results on August 12, 2021, after market close. The company aims to discuss these results in a conference call at 4:30 p.m. EDT on the same day, featuring CEO Dwight Egan and CFO Brian Brown. Co-Diagnostics focuses on molecular diagnostics with a patented technology for developing diagnostic tests based on nucleic acid detection. The results and call are crucial for investors seeking insights into the company's financial performance and future outlook.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced the award of a new patent for its CoPrimer™ technology from South Korea's Intellectual Property Office. This adds to the company's growing portfolio of intellectual property, enhancing the protection of its molecular diagnostic tests. The CoPrimer technology underpins tests like the Logix Smart™ COVID-19 Test kit, which has sold millions globally since the pandemic's onset. Co-Diagnostics emphasizes the durability of its sales model and the significant demand from repeat customers.
Co-Diagnostics, Inc. (CODX) announced that its Logix Smart™ SARS-CoV-2 DS test has received regulatory authorization as an in vitro diagnostic (IVD) for COVID-19 detection in markets accepting CE markings. This test allows for direct saliva sampling, eliminating the need for RNA extraction, which can reduce costs and increase testing throughput. CEO Dwight Egan emphasized that this innovation could significantly aid in ongoing testing efforts, especially in areas lagging in vaccination rates. The CE marking facilitates immediate sales in the European Community and other global markets.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) will present virtually at the 28th International Biodetection Technologies Conference on June 18. The focus will be on point-of-care diagnostics to enhance global health and biodefense. The company's presentation at 12:30 pm ET will detail their rapid PCR testing platform aimed at normalizing daily activities during the COVID-19 pandemic. Additionally, Co-Diagnostics will showcase its products at the CARPHA Health Research Conference from June 16-19, focusing on health issues in the Caribbean region.
Co-Diagnostics, Inc. (Nasdaq: CODX) will release its first-quarter 2021 results on May 13, 2021, after the market close. A conference call and webcast will follow at 4:30 p.m. EDT on the same day, featuring CEO Dwight Egan and CFO Brian Brown. Investors can access the event on the company's website. Co-Diagnostics specializes in developing and marketing advanced molecular diagnostic tests using unique technology for detecting nucleic acid molecules, and provides licensing for specific tests across various industries.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its participation in a webinar on April 29, 2021, featuring Dr. Heather Fehling from Clinical Reference Lab. The event will discuss PCR testing for COVID-19, highlighting non-invasive saliva tests and new applications in response to emerging strains. Co-Diagnostics’ technology is used in CRL's saliva PCR test, which boasts high sensitivity and specificity, with results typically available in 24 hours. This initiative aims to enhance testing accessibility and application in various settings.
Summary not available.